27 Oct 2014 14:29

For immediate release | 27 October 2014 |
ABCAM PLC
("Abcam" or "the Company")
Director's dealings
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that following completion of three years of continued employment since the award of Free Shares and Matching Shares on 26 October 2011 under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of each Director as follows:
Free Shares now transferred to beneficial ownership | Matching Shares now transferred to beneficial ownership* | Total subsequent beneficial holding | Percentage of share capital | |
Jim Warwick | 870 | 436 | 3,005,908 | 1.50% |
Jeff Iliffe | 870 | 436 | 327,758 | 0.16% |
\* The number of matching shares is determined by the individual's election to purchase shares within the Share Incentive Plan limits. Any contribution which is unable to purchase a whole ordinary share at market value on the date of award is rolled forward for future share awards.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Alan Hirzel / Jeff Iliffe  | |
Numis Securities - Nominated Adviser and Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking  | |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking  | |
Brunswick | + 44 (0) 20 7404 5959 |
Justine Mcllroy / Robin Wrench / Emma Walsh |
Â
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Â
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Â
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
Â
To find out more, please visit www.abcam.com